FIELD: medicine.
SUBSTANCE: invention refers to new human insulin derivatives which are soluble at physiological pH values. The invention also refers to methods for preparing such derivatives, to pharmaceutical compositions containing them, to methods of treating diabetes and hyperglycaemia with using insulin derivatives under the invention and to the use such insulin derivatives in treating diabetes and hyperglycaemia.
EFFECT: prolonged profile of derivative action.
16 cl, 21 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| INSULIN PURIFICATION | 2012 |
|
RU2603752C2 |
| METHOD OF CONJUGATING PEPTIDES, MEDIATED BY TRANSGLUTAMINASE | 2005 |
|
RU2385879C2 |
| INSULIN DERIVATIVES | 2004 |
|
RU2352581C2 |
| INSULIN DERIVATIVES | 2004 |
|
RU2518460C2 |
| TREATING DIABETES MELLITUS BY INSULIN INJECTIONS AS LITTLE AS ONCE DAY | 2009 |
|
RU2540922C2 |
| INSULIN DERIVATIVE, SOLUBLE PROLONGED PHARMACEUTICAL COMPOSITION, METHOD OF PROLONGATION OF HYPOGLYCAEMIC EFFECT IN TREATMENT OF DIABETIC PATIENTS | 1994 |
|
RU2164520C2 |
| PHARMACEUTICAL COMPOSITION | 2013 |
|
RU2670106C2 |
| GLP-1 DERIVATIVES | 1997 |
|
RU2214419C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
| METHOD OF OBTAINING INSULIN ZINC COMPLEXES | 2011 |
|
RU2572214C2 |
